Skip to main content
Clinical Trials/NCT05450757
NCT05450757
Recruiting
Not Applicable

A Prospective Multicentre Cohort Study of Acute ST-segment Elevation Myocardial Infarction

Ruijin Hospital7 sites in 1 country2,000 target enrollmentSeptember 12, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
ST Elevation Myocardial Infarction
Sponsor
Ruijin Hospital
Enrollment
2000
Locations
7
Primary Endpoint
MACE
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

ST-segment elevation myocardial infarction(STEMI) remains a major cause of morbidity and mortality worldwide, despite of the early reperfusion therapy, including fibrinolysis, primary percutaneous coronary intervention (PCI),and standardized medical treatment.To improve the prognosis of STEMI patients, the management in their hospitalization should be optimized, including improvements in risk stratification, more widespread use of an invasive strategy, implementation of care delivery systems prioritising immediate revascularisation through PCI (or fibrinolysis), advances in antiplatelet agents and anticoagulants, and greater use of secondary prevention strategies such as lipid-lowering therapy.

This study aims to standardized the management of STEMI patients and improve the prognosis of the STEMI patients.

Detailed Description

This study is a prospective cohort study. It aims to standardized the management of STEMI patients and improve the prognosis of the STEMI patients.

Registry
clinicaltrials.gov
Start Date
September 12, 2018
End Date
September 17, 2024
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

RUIYAN ZHANG

Director of Cardiology Department, Chief Physician

Ruijin Hospital

Eligibility Criteria

Inclusion Criteria

  • ST elevation myocardial infarction
  • Coronary angiography and percutaneous coronary intervention within 12 hours of symptom onset
  • Capable and willing to provide informed conset and capable of completing study visits

Exclusion Criteria

  • Cardiovascular shock at admission
  • Severe physical disability
  • Active malignant tumors
  • Active autoimmune diseases

Outcomes

Primary Outcomes

MACE

Time Frame: 0-1 year

Major adverse cardiovascular events(MACE) in one year follow-up

Left Ventricular Function

Time Frame: 1 month, 6month and 1 year

Left ventricular end diastolic volume(LVEDV),Left ventricular end systolic volume(LVESE),Left ventricular ejection fraction(LVEF) changes within one year follow-up

Coronary angiography

Time Frame: 1 year

The pathological changes in culprit vessels in 1 year

Study Sites (7)

Loading locations...

Similar Trials